262 related articles for article (PubMed ID: 30973790)
1. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Caviglia S; Avino F; Cortesi L; Taverniti C; Pacquola MG; Falcini F; Gulisano M; Digennaro M; Cariello A; Cagossi K; Pinotti G; Lazzeroni M; Serrano D; Branchi D; Campora S; Petrera M; Buttiron Webber T; Boni L; Bonanni B
J Clin Oncol; 2019 Jul; 37(19):1629-1637. PubMed ID: 30973790
[TBL] [Abstract][Full Text] [Related]
2. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M; Puntoni M; Guerrieri-Gonzaga A; Serrano D; Boni L; Buttiron Webber T; Fava M; Briata IM; Giordano L; Digennaro M; Cortesi L; Falcini F; Serra P; Avino F; Millo F; Cagossi K; Gallerani E; De Simone A; Cariello A; Aprile G; Renne M; Bonanni B; DeCensi A
J Clin Oncol; 2023 Jun; 41(17):3116-3121. PubMed ID: 36917758
[TBL] [Abstract][Full Text] [Related]
3. Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast.
Lazzeroni M; Puntoni M; Provinciali N; Webber TB; Briata IM; D'Amico M; Giuliano S; Siri G; Cagnacci S; DeCensi A
Breast; 2019 Nov; 48 Suppl 1():S39-S43. PubMed ID: 31839158
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
5. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
6. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
8. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.
Guerrieri-Gonzaga A; Botteri E; Lazzeroni M; Rotmensz N; Goldhirsch A; Varricchio C; Serrano D; Cazzaniga M; Bassi F; Luini A; Bagnardi V; Viale G; Mora S; Bollani G; Albertazzi E; Bonanni B; Decensi A
Ann Oncol; 2010 May; 21(5):949-54. PubMed ID: 19858087
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.
Guerrieri-Gonzaga A; Lazzeroni M; Botteri E; Serrano D; Rotmensz N; Varricchio MC; Cazzaniga M; Bollani G; Mora S; Montefrancesco C; Pruneri G; Viale G; Intra M; Galimberti V; Goldhirsch A; Bagnardi V; Bonanni B; DeCensi A
Ann Oncol; 2013 Jul; 24(7):1859-1866. PubMed ID: 23532115
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract][Full Text] [Related]
11. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
13. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.
Llarena NC; Estevez SL; Tucker SL; Jeruss JS
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307641
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
16. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
17. Uterine sarcoma after tamoxifen therapy for breast cancer.
Samuji M; O'Sullivan R; Shireen R
Ir Med J; 2013 Sep; 106(8):246. PubMed ID: 24282897
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]